Cantor Fitzgerald gave Western Digital an overweight rating, and Morgan Stanley raised its target price for the company.
4 reports, 1 independent
Updated Aug 30
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald gave Western Digital an overweight rating, and Morgan Stanley raised its target price for the company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Western Digital
American computer storage corporation
-
Morgan Stanley
U.S. investment bank
- Jefferies Financial Group began coverage, Morgan Stanley set a high price target, and Keefe, Bruyette & Woods increased price objectives, with MarketBeat reporting the average stock rating.
- Reports from August 2025 detail how major tech companies (Microsoft, Google, Meta, Amazon) are driving massive investments in data centers and AI infrastructure.
-
Cantor Fitzgerald
American financial services company
- Rating firms Raymond James Financial, Cantor Fitzgerald, and Truist Financial issued updates, including buy ratings and price targets, for First Industrial Realty Trust on June 19, 2026.
- Morgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron Pharmaceuticals stock.
Related events
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
- Cantor Fitzgerald reiterated an overweight rating for Sterling Infrastructure on November 1, 2026.
- Barclays dropped its target price and set an underweight rating, while Cantor Fitzgerald also issued an underweight rating for Polestar.
- Cantor Fitzgerald restated an overweight rating for Anteris Technologies Global Corp. on October 8, 2026.
- Cantor Fitzgerald restated an overweight rating and Royal Bank of Canada reduced its price objective for United Therapeutics.